Atrimustine

Atrimustine is a conjugate of chlorambucil and β-estradiol benzoate with the antitumor activity.

Product Specifications

CAS Number

[75219-46-4]

Product Name Alternative

Bestrabucil; KM2210

UNSPSC

12352005

Target

Others

Type

Reference compound

Related Pathways

Others

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Atrimustine.html

Purity

98.88

Solubility

DMSO : 16.67 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

C[C@@]1([C@H]2OC(COC(CCCC3=CC=C(N(CCCl)CCCl)C=C3)=O)=O)[C@](CC2)([H])[C@@](CCC4=CC(OC(C5=CC=CC=C5)=O)=CC=C64)([H])[C@]6([H])CC1

Molecular Formula

C41H47Cl2NO6

Molecular Weight

720.72

References & Citations

[1]Ezaki K, et al. A combination trial of human lymphoblastoid interferon and bestrabucil (KM2210) for adult T-cell leukemia-lymphoma. Cancer. 1991 Aug 15;68 (4) :695-8.|[2]Akaza H, et al. Inhibitory effects of bestrabucil, a conjugate of chlorambucil and estradiol, on the production of androgen-induced growth factor (s) by Shionogi carcinoma 115 cells. Int J Urol. 1994 Mar;1 (1) :67-73.